The American Society of Clinical Oncologists has updated the clinical practice guidelines for metastatic breast cancer for bone-modifying agents.The update added the FDA recently-approved denosumab (Xgeva®), as another option for preventing and treating skeletal-related events (SRE); the other two drugs are pamidronate (Aredia®) and zoledronic acid (Zometa®). The guidelines now also include information about osteonecrosis of the jaw, a rare side effect associated with the use of all three drugs.
Catherine H. Van Poznak, Sarah Temin, Gary C. Yee, Nora A. Janjan, William E. Barlow, J. Sybil Biermann, Linda D. Bosserman, Cindy Geoghegan, Bruce E. Hillner, Richard L. Theriault, Dan S. Zuckerman and Jamie H. Von Roenn. American Society of Clinical Oncology Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer. In Journal of Clinical Oncology, March 20, 2011 vol. 29 no. 9 1221-12275 6 7 8 © 2004-2010 Donna Peach. All rights reserved.